At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 61 enrolled
Drug / intervention
Morphine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
In Brief
A Phase 4 clinical trial evaluating Morphine and Methadone for Neonatal Abstinence Syndrome. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This study investigates the use of methadone versus morphine wean for the treatment of neonatal abstinence syndrome for infants exposed to opioids in utero. Half of infants who require pharmacotherapy for NAS will receive a methadone wean, and half will receive a morphine wean. Length of hospital stay, length of treatment and parent satisfaction will be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeonatal Abstinence Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionJun 2018
Study CompletionSep 2018
TodayJul 2026
First PostedAug 1, 2016
Enrollment StartOct 1, 2016
Primary CompletionJun 1, 2018
Study CompletionSep 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.9 years ago
Interventions
Morphinedrug
Morphine wean protocol as described in arm description
Methadonedrug
Methadone wean protocol as described in arm description